Sickle cell diseaseNews & Research
16 curated articles for Sickle cell disease — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Pediatric blood & cancer Apr 22, 2026
Clinical Practice Patterns for Discussing Hydroxyurea Initiation With Families of Children With Sickle Cell Disease.
Despite robust evidence of safety and efficacy, hydroxyurea (HU) uptake remains low for children with sickle cell disease (SCD). Guidelines recommend use of shared decision-making for HU initiation, but limited resources exist to inform these conversations with families. This study examined practice...
Why it matters: Recent peer-reviewed research on Sickle cell disease that may be relevant for patients and caregivers.
- Journal of assisted reproduction and genetics Apr 22, 2026
Effectiveness of preimplantation genetic testing in sickle cell disease: insights from a single-center experience.
Sickle-cell disease (SCD) is a severe autosomal recessive disorder. At-risk couples may prevent transmission either through prenatal diagnosis with possible termination of pregnancy or preimplantation genetic testing for monogenic disease (PGT-M). Data on PGT-M outcomes in this population remain sca...
Why it matters: Recent peer-reviewed research on Sickle cell disease that may be relevant for patients and caregivers.
- Journal of pediatric hematology/oncology nursing Apr 20, 2026
Gene Therapy for Sickle Cell Disease.
BackgroundSickle cell disease (SCD) is a genetic blood disorder in which sickled red blood cells cannot easily pass through the vasculature, leading to impaired tissue perfusion and oxygenation that can lead to vaso-occlusive pain, stroke, and multiorgan and tissue damage. Scientists have now develo...
Why it matters: Recent peer-reviewed research on Sickle cell disease that may be relevant for patients and caregivers.
- Advanced healthcare materials Apr 17, 2026
Hemoglobin as a Molecular Glue: Toward Potent Inhibition of HbS Polymerization in Sickle Cell Disease.
Sickle cell disease (SCD), a monogenic disorder arising from a single point mutation in the β-globin gene, continues to pose a significant global health burden despite advances in supportive care. This mutation drives the formation of hemoglobin S (HbS) polymers under deoxygenated conditions, ...
Why it matters: Recent peer-reviewed research on Sickle cell disease that may be relevant for patients and caregivers.
- Archives of biochemistry and biophysics Apr 11, 2026
Myeloperoxidase in the pathogenesis of sickle cell disease.
Sickle cell disease (SCD) is an inherited disorder characterized by abnormal hemoglobin molecules that cause the sickling of red blood cells (RBCs) which occlude blood vessels, increase hemolysis, and leads to chronic inflammation. Accumulating evidence has strongly linked SCD and other inflammatory...
Why it matters: Recent peer-reviewed research on Sickle cell disease that may be relevant for patients and caregivers.
- Blood Mar 26, 2026
Benchmarking clonal hematopoiesis in sickle cell disease.
Benchmarking clonal hematopoiesis in sickle cell disease.
Why it matters: Recent peer-reviewed research on Sickle cell disease that may be relevant for patients and caregivers.
- Blood Mar 26, 2026
Increased prevalence of clonal hematopoiesis in children with sickle cell disease.
Recent studies have reached opposing conclusions about whether clonal hematopoiesis (CH) is increased or decreased in patients with sickle cell disease (SCD). Given that CH is typically age-related, its presence in children with SCD could offer unique insights into early-life mutagenesis and disease...
Why it matters: Recent peer-reviewed research on Sickle cell disease that may be relevant for patients and caregivers.
- Lancet (London, England) Mar 14, 2026
Back to basics in sickle cell disease.
Back to basics in sickle cell disease.
Why it matters: Recent peer-reviewed research on Sickle cell disease that may be relevant for patients and caregivers.
- Lancet (London, England) Mar 14, 2026
Sickle cell disease.
Sickle cell disease is a genetic red blood cell disorder, affecting millions of people globally. This Seminar provides a comprehensive update on the disease, emphasising its complex pathophysiology involving sickle haemoglobin polymerisation, vaso-occlusion, haemolysis, and inflammation that lead to...
Why it matters: Recent peer-reviewed research on Sickle cell disease that may be relevant for patients and caregivers.
- Cureus Mar 12, 2026
Adolescent Cholelithiasis: Evolving Challenges and Clinical Implications.
Gallstone disease in adolescents is no longer a rare clinical finding and has become an increasingly important concern in pediatric and adolescent healthcare. Shifts in lifestyle, rising rates of obesity, and improved survival of children with chronic conditions such as sickle cell disease have coll...
Why it matters: Recent peer-reviewed research on Sickle cell disease that may be relevant for patients and caregivers.
- Cells Mar 5, 2026
Rethinking Sickle Cell Disease as a Systemic Vasculopathy.
Sickle cell disease (SCD) is the most common inherited clinically relevant blood disorder. Although a deceptively simple monogenetic disorder, the associated complications have multiple downstream effects. In this review, we explore the many facets of SCD, with a particular focus on its impact on th...
Why it matters: Recent peer-reviewed research on Sickle cell disease that may be relevant for patients and caregivers.
- Journal of community genetics Mar 4, 2026
Role of the primary healthcare providers in sickle cell disease management: a scoping review.
The primary healthcare (PHC) system is essential for facilitating adherence to care practices among patients with sickle cell disease (SCD). While the PHC system is being strengthened widely, effective disease management is often seen as compromised. This review emphasizes the pivotal role of primar...
Why it matters: Recent peer-reviewed research on Sickle cell disease that may be relevant for patients and caregivers.
- BreakingBlood Advances Mar 1, 2026
Sickle Cell Gene Therapy: Real-World Outcomes from First 50 Patients
Early real-world data shows vaso-occlusive crisis elimination in 89% of patients at 6 months post-treatment.
Why it matters: Real-world results matching trial data. Gene therapy delivering on its promise.
- Orthopaedics & traumatology, surgery & research : OTSR Feb 13, 2026
Orthopedic complications of sickle-cell disease in children.
Sickle cell disease is the most common serious genetic disease in the world. It is a systemic disease, characterized by vaso-occlusive phenomena, especially in the bone capillary network. Orthopedic complications are thus the most common, with a strong impact on quality of life. In children, these c...
Why it matters: Recent peer-reviewed research on Sickle cell disease that may be relevant for patients and caregivers.
- NotableNature Medicine Dec 20, 2025
CRISPR Base Editing Advances Toward Rare Disease Therapies
Beam Therapeutics reported positive interim data from base editing for sickle cell disease, showing efficient editing without double-strand DNA breaks.
Why it matters: Base editing may be safer than traditional CRISPR, expanding gene therapy to more rare diseases.
- BreakingFDA Dec 8, 2025
FDA Approves First Gene Therapies for Sickle Cell Disease
The FDA approved Casgevy and Lyfgenia, the first cell-based gene therapies for sickle cell disease. Casgevy is the first FDA-approved therapy utilizing CRISPR/Cas9 gene editing.
Why it matters: First CRISPR-based therapy ever approved. Opens door for gene editing across rare diseases.
More on Sickle cell disease
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.